Story · Medicine & Biotech · Mind & Brain

Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression

1 outlet · first reported by MedPage Today 4d ago

Coverage, in order

  1. 4d ago
    MedPage Today indie randomized trial
    Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression

    (MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.